Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes

REFERENCES

• Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853–61
   PubMed Web of Science ®Google Scholar
• Hull MGR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1987;1:235–45
   PubMedGoogle Scholar
• Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 1986;293:355–9
   PubMed Web of Science ®Google Scholar
• Speroff L, Glass RH, Kase NG. Anovulation and the polycystic ovary. In Speroff L, ed. Clinical Gynecologic Endocrinology and Infertility. Baltimore, USA: Lippincott Williams & Wilkins, 1999:487–521
   Google Scholar
• Hopkinson ZEC, Sattar N, Fleming R, et al. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. Br Med J 1998;317:329–32
   PubMed Web of Science ®Google Scholar
• Will R. Obesity, lipids, cardiovascular risk and androgen excess. Am J Med 1995; 98(Suppl 1A):27S–32S
   Google Scholar
• Dunaif A, Segal KR, Shelley DR, et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41:1257–66
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and ovarian hyperandrogen- ism. Endocrinologist 1992;2:248–60
   Google Scholar
• Barbieri R, Smith S, Ryan K. The role of hyperinsuli- nemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988;50:197–212
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800
   PubMed Web of Science ®Google Scholar
• Dunaif A. Hyperandrogenic anovulation (PCOs): a unique disorder of insulin action associated with an increased risk of non-insulin dependent diabetes mellitus. Am J Med 1995; 98(Suppl 1A):33S–39S
   Google Scholar
• Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovarian syndrome. Arterioscler Thromb Vasc Biol 1995;15:821–6
   PubMed Web of Science ®Google Scholar
• Dahlgren E, Janson PO, Johansson S, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992;57:505–13
   PubMed Web of Science ®Google Scholar
• Birdsall MA, Farquar CM, White HD. Association between polycystic ovaries and the extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997;126:32–5
   PubMed Web of Science ®Google Scholar
• Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective study of women. Acta Obstet Gynecol Scand 1992;71:599–604
   Google Scholar
• van der Vange N, Blankenstein MA, Kloosterboer HJ, et al. Effects of seven low-dose combined oral contra- ceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contra- ception 1990;41:345–52
   PubMed Web of Science ®Google Scholar
• Coenen CM, Thomas CM, Borm GF, et al. Changes in androgens during treatment with four low-dose contra- ceptives. Contraception 1996;53:171–6
   PubMed Web of Science ®Google Scholar
• Falsetti L, Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception 1990;42:611–19
   PubMed Web of Science ®Google Scholar
• Aydinlik S, Kaufmann J, Lachnit-Fixson U, et al. Long- term therapy of signs of androgenisation with a low- dosed antiandrogen-oestrogen combination. Clin Trials J 1990;27:392–402
   Google Scholar
• Erenus M, Yucelten D, Gurbuz O, et al. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Fertil Steril 1996;66:216–19
   PubMed Web of Science ®Google Scholar
• Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990;323:1375–81
   PubMed Web of Science ®Google Scholar
• Schiele F, Vincent-Viry M, Fournier B, et al. Biological effects of eleven combined oral contraceptives on serum triglycerides, gamma-glutamyltransferase, alkaline phos- phatase, bilirubin and other biochemical variables. Clin Chem Lab Med 1998;36:871–8
   PubMed Web of Science ®Google Scholar
• Polderman KH, Gooren LJG, Asscheman H, et al. Induction of insulin resistance by androgens and estro- gens. J Clin Endocrinol Metab 1994;79:265–71
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–7
   PubMed Web of Science ®Google Scholar
• Fox R, Corrigan E, Thomas PA, et al. The diagnosis of polycystic ovaries in women with oligo-amenorrhea: predictive power of endocrine tests. Clin Endocrinol (Oxf) 1991;34:127–31
   PubMed Web of Science ®Google Scholar
• Bonora E, Moghetti P, Zancanaro C, et al. Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab 1989;68:374–8
   PubMed Web of Science ®Google Scholar
• Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999;84:1304–10
   PubMed Web of Science ®Google Scholar
• Moghetti P, Tosi F, Castello R, et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: Evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996;81:952–60
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Evans WS, et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;336:1876–80
   Google Scholar
• Dunaif A, Scott D, Finegood D, et al. The insulin- sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:3299–306
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17-alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617–23
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Cavaghan MK, Imperial J, et al. Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:524–30
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139–46
   PubMed Web of Science ®Google Scholar
• Vexiau P, Vexiau-Robert D, Martineau I, et al. Metabolic effect at six and twelve months of cyproterone acetate (2 mg) combined with ethinyl estradiol (35 mg) in 31 patients. Horm Metab Res 1990;22:241–5
   PubMed Web of Science ®Google Scholar
• De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214–E223
   PubMed Web of Science ®Google Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000;85:3161–8
   PubMed Web of Science ®Google Scholar
• Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex-hormone binding glo- bulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83–9
   PubMed Web of Science ®Google Scholar
• Preziosi P, Barrett-Connor E, Papoz L, et al. Interrelation between plasma sex hormone-binding globulin and plasma insulin in healthy adult women: the Telecom Study. J Clin Endocrinol Metab 1993;76:283–7
   PubMed Web of Science ®Google Scholar
• Granger LR, Roy S, Mishell DR. Changes in unbound sex steroids and sex hormone binding globulin-binding capacity during oral and vaginal preestrogen administra- tion. Am J Obstet Gynecol 1982;144:578–84
   PubMed Web of Science ®Google Scholar